Financials
Financial year 2025
PHARMA BIO CONSULT from Tournai, company number BE0719347149, closed financial year 2025 with a result of € 156,029 after tax. For that financial year PHARMA BIO CONSULT recorded a gross margin of € 48,990 and equity of € 34,629. Compared with financial year 2024, the result moved from € 35,791 to € 156,029. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.
€ 34,629
▲ 86% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 156,029
▲ € 120,238 vs 2024
Profit after tax over the fiscal year.
€ 104,058
▲ € 98,367 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 140,000 paid out
90 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 29,645
▲ 52% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 29,005
▲ 24% vs 2024
€ 9,220 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 2,869
▲ 237% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 6,464
▼ 56% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 51,505 | € 52,233 | € 63,903 | € 48,990 | ▼ 23% |
| Profit after taxes | € 32,720 | € 24,135 | € 35,791 | € 156,029 | ▲ € 120,238 |
| Equity | € 18,600 | € 18,600 | € 18,600 | € 34,629 | ▲ 86% |
| Total debts | € 92,064 | € 65,434 | € 69,812 | € 121,026 | ▲ 73% |
| Cash | € 383 | € 404 | € 5,691 | € 104,058 | ▲ € 98,367 |
| Retained profit | € 0 | € 0 | € 0 | € 16,029 | |
| Dividend | € 126,565 | € 24,135 | € 35,791 | € 140,000 | ▲ 291% |
| Bank debt | € 47,796 | € 36,421 | € 23,343 | € 29,005 | ▲ 24% |
| Balance sheet total | € 110,664 | € 84,034 | € 88,412 | € 155,655 | ▲ 76% |
Key figures of PHARMA BIO CONSULT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA BIO CONSULT?
What happened at PHARMA BIO CONSULT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 156,029 (▲ € 120,238 vs 2024). Source: NBB ↗
- Franck Polyn became a director. NBB
- New establishment in Tournai. KBO
- Start of the company according to the CBE. KBO
In short
From € 32,720 profit in 2022 to € 156,029 profit in 2025.
Paid € 78,822 in corporate taxes since 2022.
Best year ever: 2025, with € 156,029 profit.
Paid out € 326,492 in dividends to the owners in total.
Management
Behind PHARMA BIO CONSULT is Franck Polyn. Franck Polyn is also behind LSB - BELGIQUE.
Directors
According to the 2025 annual accounts
since 2021
Establishments
Establishment units
Physical locations of this company
Chaussée de Lille(TOU) 236
7500 Tournai
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0719.347.149
- VAT number
- BE 0719.347.149
- Registered office
- Chaussée de Lille(TOU) 236, 7500 Tournai
- Names & denominations
- PHARMA BIO CONSULT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 January 2019
- Peppol
- Active · Active since 6 Oct 2025
- Activities · NACE
Overige technische testen en toetsen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige gespecialiseerde wetenschappelijke en technische activiteiten